Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai to Continue “Price Zero” Drug Supply to Stamp Out Lymphatic Filariasis
April 20, 2017
- Burosumab Hits Primary Endpoint in PIII for Adult X-Linked Hypophosphatemia: Kyowa Kirin
April 20, 2017
- “Headquarters Involvement Clear” in Access to Patient Medical Charts by Bayer Sales Reps: Attorney for Whistleblower
April 20, 2017
- Xarelto Issue Morally Questionable, but Does Not Constitute Misleading Ads Banned under Law: MHLW Officials
April 20, 2017
- Japan Vaccine Files New Shingles Vaccine: GSK
April 19, 2017
- Biogen’s Sugino to Lead Amgen Astellas; R&D Head Torii Named Successor
April 19, 2017
- AZ Boosting Field Force Specialization with Move to Business Units: Japan Chief
April 19, 2017
- Fujifilm Completes Bio Production Facility in US, Aiming to Initiate Operations in Early 2018
April 19, 2017
- Ex-Takeda Exec Noguchi Becomes President of Celgene Japan
April 18, 2017
- Boehringer Japan Logs 14 Consecutive Years of Growth in Ethical Drug Sales
April 18, 2017
- Celgene Submits Biz Improvement Plan over Side Effect Reporting Violation
April 18, 2017
- Japan Hemophilia Market Likely to Expand to Nearly 70 Billion Yen in 2024: Fuji Keizai
April 17, 2017
- Takecab Most Promoted Drug in HP Market for 4th Month in February: Anterio
April 17, 2017
- Shionogi Files Japan NDA for Another Shire-Licensed ADHD Med
April 14, 2017
- Takeda Chairman Hasegawa to Retire, Become Adviser in June
April 14, 2017
- Sales Rep and Doctor at Center of Xarelto Survey Scandal Conflict over “Patient Consent”
April 14, 2017
- Novo Japan Chalks Up Record Sales in 2016 on Tresiba, Victoza
April 13, 2017
- Bayer Apologizes for Employees’ “Improper” Involvement in Xarelto Survey, Whistleblower Says He Browsed Charts for over 200 Patients
April 12, 2017
- 1st Herceptin Biosimilar Filed in Japan: Nippon Kayaku
April 12, 2017
- Takeda Strikes Microbiome Deal with Canada’s NuBiyota
April 12, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…